(NASDAQ: AMPH) Amphastar Pharmaceuticals's forecast annual revenue growth rate of 1.67% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Amphastar Pharmaceuticals's revenue in 2025 is $730,659,000.On average, 3 Wall Street analysts forecast AMPH's revenue for 2025 to be $34,054,500,620, with the lowest AMPH revenue forecast at $33,638,451,056, and the highest AMPH revenue forecast at $34,396,447,543. On average, 3 Wall Street analysts forecast AMPH's revenue for 2026 to be $35,025,754,328, with the lowest AMPH revenue forecast at $34,222,975,710, and the highest AMPH revenue forecast at $36,117,495,536.
In 2027, AMPH is forecast to generate $36,241,942,721 in revenue, with the lowest revenue forecast at $34,477,526,769 and the highest revenue forecast at $38,483,877,603.